MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1798)	11/12/2007 11:31:54 AM
From: Icebrg	Read Replies (2) of 1826

MGI Pharma downgraded to "sell" Monday, November 12, 2007 9:25:52 AM ET Brean Murray, Carret & Co NEW YORK, November 12 (newratings.com) - Analysts at Brean Murray downgrade MGI Pharma (MOGN.NAS) from "hold" to "sell," while reducing their estimates for the company. In a research note published this morning, the analysts mention that the company's Dacogen drug is unlikely to show a survival benefit higher than or equal to that of Vidaza. The analysts do not expect MGI Pharma's Aquavan drug to receive direct approval for a specific indication. The sales of the company's Aloxi drug in the PONV indication are expected to be low, Brean Murray adds. MGI Pharma does not seem to be an attractive takeover candidate due to substantial risks associated with the company's development programmes, the analysts state. The EPS estimates for 2007 and 2008 have been reduced from -$0.14 to -$0.16 and from $1.29 to $0.89, respectively.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next